Array BioPharma (ARRY) PT Raised to $24 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Array BioPharma (ARRY) PT Raised to $23 at Cowen
February 6, 2019 7:56 AM ESTCowen analyst Chris Shibutani raised the price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $22.00) while maintaining a Outperform rating.
The analyst commented, "Delivery of another excellent quarter, with F2Q19 MEKTOVI/BRAFTOVI sales of $23MM handily outpacing expectations, bolsters confidence in... More
Array BioPharma (ARRY) PT Raised to $29 at Stifel
February 5, 2019 3:55 PM ESTStifel analyst Stephen Willey raised the price target on Array BioPharma (NASDAQ: ARRY) to $29.00 (from $26.00) while maintaining a Buy rating.
Willey said Q2 confirms the value of the melanoma opportunity.
... MoreArray BioPharma (ARRY) PT Raised to $34 at Guggenheim
February 5, 2019 11:57 AM ESTGuggenheim analyst Michael Schmidt raised the price target on Array BioPharma (NASDAQ: ARRY) to $34.00 (from $33.00) while maintaining a Buy rating.
... MoreArray Biopharma (ARRY) Tops Q2 EPS by 10c, Revenues Beat
February 5, 2019 8:02 AM ESTArray Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.05), $0.10 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $82.5 million versus the consensus estimate of $52.45 million.
Second Quarter of Fiscal 2019 Compared to First Quarter of Fiscal 2019
Net Product Sales for BRAFTOVI + MEKTOVI for the second quarter of fiscal 2019 was $22.7 million, compared to $14.0 million for the first quarter of fiscal 2019.Total Revenue for the second quarter of fiscal 2019 was $82.5 million, compared to $56.9 million for the prior quarter. The increase was primarily due to higher product sales and... More